Skip to the page

Data / Drug companies / Qingdao Baheal Pharmaceutical Co., Ltd.

Qingdao Baheal Pharmaceutical Co., Ltd.: 9 products in the FDA NDC directory, labeler code 70247

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Qingdao Baheal Pharmaceutical Co., Ltd. (labeler code 70247) lists 9 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 9 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 27, 2018.

The request: Watch Qingdao Baheal Pharmaceutical Co., Ltd. (FDA labeler code 70247): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70247
Products in commercial distribution
9
Packages
15
Finished drugs by generic name
3
Prescription products
9
Over the counter products
0
Flagged as original packager
9 of 9 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
October 10, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)9100%

Products by type

TypeProductsShare
Prescription drugs9100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule444.4%
Capsule, delayed release333.3%
Tablet, film coated, extended release222.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Metformin Hydrochloride70247-019Tablet, film coated, extended releaseGeneric drugs (ANDA)December 27, 2018
Metformin Hydrochloride70247-018Tablet, film coated, extended releaseGeneric drugs (ANDA)December 27, 2018
Duloxetine70247-014Capsule, delayed releaseGeneric drugs (ANDA)May 5, 2018
Duloxetine70247-013Capsule, delayed releaseGeneric drugs (ANDA)May 5, 2018
Duloxetine70247-012Capsule, delayed releaseGeneric drugs (ANDA)May 5, 2018
Celecoxib70247-009CapsuleGeneric drugs (ANDA)October 10, 2016
Celecoxib70247-008CapsuleGeneric drugs (ANDA)October 10, 2016
Celecoxib70247-007CapsuleGeneric drugs (ANDA)October 10, 2016
Celecoxib70247-006CapsuleGeneric drugs (ANDA)October 10, 2016

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.